RxDoctor Payments Data

Andrew Krouner, MD

Ophthalmology · Wexford, PANPI 1740294255

Payments from drug & device makers

$2,154in general payments, 2019–2025

Across 94 payments — averaging $22.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$381
  • Astellas Pharma US Inc$291
  • Oyster Point Pharma, Inc.$282
  • Sun Pharmaceutical Industries Inc.$221
  • Alcon$195
  • AbbVie$117
  • plus $667 from 12 others

What the payments were for

  • Food & beverage$2,154100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,154 in reported general payments places this provider in the 60th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$143,339
Medicare patients
825
Services billed
1,461

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine46$61,680
XiidraLifitegrast35$49,100
LumiganBimatoprost68$33,900
VyzultaLatanoprostene Bunod49$19,480
Cyclosporine56$18,876
Travoprost66$12,104
SimbrinzaBrinzolamide/Brimonidine Tart36$9,992
CombiganBrimonidine Tartrate/Timolol38$9,164
Brimonidine Tartrate109$8,688
Loteprednol Etabonate29$6,791
Timolol Maleate265$6,344
Latanoprost622$6,057
Fluorometholone73$5,243
Brinzolamide27$5,106
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol30$4,020

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$117$108,366163 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$92$68,58084 claims
AlconSimbrinza$195$9,99236 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$76$6,79129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Wexford

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →